| Names | |
|---|---|
| Preferred IUPAC name | Sodium (6R,7R)-3-[(acetoxy)methyl]-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Other names | Claforan Cepotaxime Cefotaxim Natrium Cefotaximum Cefotaximum Sodium |
| Pronunciation | /ˌsɛfəˈtæk.siːm ˈsoʊdi.əm/ |
| Identifiers | |
| CAS Number | 64485-93-4 |
| Beilstein Reference | 7417030 |
| ChEBI | CHEBI:3527 |
| ChEMBL | CHEMBL1436 |
| ChemSpider | 20787273 |
| DrugBank | DB00493 |
| ECHA InfoCard | 100.036.056 |
| EC Number | 200-535-8 |
| Gmelin Reference | 1454889 |
| KEGG | D07620 |
| MeSH | D003023 |
| PubChem CID | 6474411 |
| RTECS number | WX2NWY0858 |
| UNII | 7T49E4JK49 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID8048452 |
| Properties | |
| Chemical formula | C16H16N5NaO7S2 |
| Molar mass | 477.481 g/mol |
| Appearance | White to yellowish, crystalline powder |
| Odor | Odorless |
| Density | 1.64 g/cm3 |
| Solubility in water | Very soluble in water |
| log P | -2.0 |
| Acidity (pKa) | 2.1 |
| Basicity (pKb) | 2.73 |
| Dipole moment | 4.61 D |
| Pharmacology | |
| ATC code | J01DD01 |
| Hazards | |
| Main hazards | May cause allergic reactions, gastrointestinal disturbances, hematologic effects, and local reactions at injection site. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | Not a hazardous substance or mixture. |
| Precautionary statements | Precautionary statements: Store below 25°C. Protect from light. Keep out of reach of children. For intravenous or intramuscular use only. Use only as directed by a physician. |
| Autoignition temperature | > 398°C (748°F) |
| Lethal dose or concentration | LD₅₀ (mouse, IV): 8000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse: 8000 mg/kg (IV) |
| NIOSH | RXC3M8SXJW |
| PEL (Permissible) | PEL (Permissible): Not established |
| REL (Recommended) | 1 g every 12 hours |
| Related compounds | |
| Related compounds | Cefotaxime Cefotaxime hydrochloride Cefotaxime acid Cephalothin Ceftriaxone Cefuroxime Ceftazidime |
| Product Identification | Description and Manufacturer Commentary |
|---|---|
| Product Name | Cefotaxime Sodium |
| IUPAC Name | Sodium (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-acetoxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Chemical Formula | C16H16N5NaO7S2 |
| Synonyms & Trade Names |
|
| CAS Number | 64485-93-4 |
| HS Code & Customs Classification |
|
From the manufacturing side, product identification forms the basis for batch release documentation and supply chain traceability. Internal coding will match the chemical identity as referenced above, with lot tracking maintained through ERP integration from synthesis lot to final shipment. Customers often require confirmation of synonyms and trade names to avoid mislabeling risks during downstream conversion, especially in cases where national pharmacopeia variances exist or regulatory market entry shifts. The chemical formula given reflects the sodium salt specific to sterile and pharmaceutical grades, matching downstream formulation needs for parenteral use. Batch-to-batch consistency of identity is managed through retention of master reference samples and analytical fingerprinting, especially for regional import and export compliance.
Cefotaxime sodium appears as a fine, almost odorless powder. Typical color ranges from off-white to pale yellow, influenced by grade, hydration state, and trace impurities inherent to synthesis or subsequent handling. Physical form and flow properties often vary between pharmaceutical and veterinary grades depending on particle size distribution and humidity content at packaging. A detectable odor signals potential degradation or contamination, warranting batch segregation.
Melting point assessment provides a crude measure of batch consistency; a depressed or broadened melting range often indicates hydrolysis or contamination. This compound decomposes before boiling, as is typical for cephalosporins, so boiling point is not a meaningful process or storage consideration. Flash point testing is not routinely performed since product use involves aqueous systems and ambient processing.
Bulk density and tapped density values inform powder handling, blending, and filling parameters. These values shift with milling, sieving, and granulation methods. High solubility in water, due to sodium salt form, is a key design factor enabling injectable formulations and process-scale dissolution. Insolubility in most organic solvents aids separation and purification stages, supporting waste minimization in process streams. Solubility profiles require re-examination upon client request for novel dosage forms or excipient changes.
Stability is compromised by moisture and elevated temperatures, resulting in loss of potency through hydrolysis of the β-lactam ring. Degradation accelerates under acidic or alkaline conditions, so solution preparation is always executed immediately prior to use. The side chain at C7 position is another site of hydrolytic or oxidative attack; this motivates careful pH and temperature control throughout synthesis, drying, and packaging. Exposure to light can cause slow structural isomerization or breakdown—an issue considered when evaluating container and storage choices.
Dissolution in sterile water forms a clear solution, provided manufacturing residuals are limited. Aggregation, precipitation, or visible turbidity reflects substandard purification, excessive excipients, or batch contamination. Dissolution characteristics are subject to validation with every scale-up, particularly when raw material sources or synthesis parameters change.
Specification parameters for cefotaxime sodium include identification, assay, purity by HPLC, pH, water content, residual solvents, and endotoxins (for injectable use). Assay and impurity limits are aligned with customer pharmacopeial or internal standards. Veterinary or industrial grades tolerate higher levels of certain byproducts, while injectable grades demand tightest limits on endotoxins and particular impurities.
| Parameter | Pharma Grade | Veterinary Grade | Industrial Grade |
|---|---|---|---|
| Assay | Defined by pharmacopeia or client spec | Lower minimum accepted | Process-dependent |
| Impurities (Total Related) | Tightly controlled | Wider range accepted | Specification based on use |
| Loss on Drying | Low required for stability | Process acceptability | Depends on application |
Major impurities stem from incomplete cyclization, sidechain hydrolysis, or over-reaction. Process design minimizes sulfoxide and desacetylated byproducts. Impurity profiles require full HPLC mapping, with tolerances set by pharmacopeias or customer specification. Each intermediate step is assured by in-process control, which includes monitoring known toxic or immunogenic derivatives.
Assay and identification rely on HPLC, IR, and UV spectroscopy methods standardized by regulatory monographs. Microbiology and endotoxin testing for parenteral grades follows compendial protocols, adjusted to process-specific needs or client regimes. Method validation is a recurring requirement as soon as new synthesis intermediates, excipients, or purification strategies are introduced.
Selection focuses on certified suppliers for 7-ACA and sodium salts, with quality, origin, and impurity content as central qualification criteria. Lot traceability allows rapid response to any reported deviations in downstream performance or purity. Each new supply lot is subject to fit-for-purpose screening to gauge its impact on key intermediates.
Synthesis moves via acylation of 7-ACA with the appropriate acid chloride, giving the core cephalosporin structure. Reaction stages are sensitive to moisture, temperature spikes, and pH deviation. Selectivity is improved through agitation, temperature ramps, and addition rates—factors routinely revisited during scale-up or tech transfer.
Process control targets include color, clarity, and intermediate purity at each stage. Impurity formation can escalate during over-reaction or incomplete removal of byproducts. Purification employs solvent extractions, crystallization, and drying under nitrogen or vacuum. Each finished batch is reviewed for residual solvents and organic/extractable contamination, with specifications drilled down by intended final use.
QA reviews both in-process and finished product data for critical identity, potency, impurity, and microbiological endpoints. For new batches or process changes, additional stress-failure and hold-time studies confirm conformance to shelf-life projections. Batches only release once full documentation and traceability are confirmed, consistent with customer and regulatory standards.
Cefotaxime sodium undergoes hydrolysis, oxidation, or aminolysis at the β-lactam or methoxyimino sidechain, giving rise to loss of potency or, if uncontrolled, to allergenic breakdown products. Industrial production avoids excesses of acid or base and restricts use of oxidizing agents to control impurity signatures.
Catalysts rarely enter direct use; process selectivity hinges on temperature, solvent, and pH. Lower temperatures and aqueous/organic phases support desired product formation without pushing side reactions. Process conditions and solvent choices are optimized regularly based on impurity drift observed in analytical release data.
Key modifications for expansion of portfolio or custom client needs include esterification for prodrug formation or salt selection for solubility/palatability improvement. Any derivative manufacturing requires separate route validation and unique release specification.
Material stores in cool, dry, well-ventilated rooms to restrict moisture pickup and premature degradation. Light-blocking containers and inert gas blankets shield against photo-oxidation and atmospheric moisture. Temperature excursions above recommended ranges precipitate rapid loss of assay and visual change in color. Product may be stored in composite, glass, or high-grade resin containers proven compatible in accelerated stability and migration studies.
Shelf life is grade-dependent and confirmed by ongoing stability programs, monitored under both ICH and customer-defined conditions. Early degradation shows as color shift, clumping, odor formation, or decline in HPLC purity. Regular visual checks at dispatch help intercept off-spec lots before shipment.
The material is classified as hazardous, reflecting potential for allergic and toxic reactions by skin contact, inhalation, or accidental ingestion. Manufacturer hazard labeling conforms to batch composition and client country of distribution.
Key hazards include respiratory sensitization and skin/eye irritation. All lines use closed-handling, dust capture, and trained staff with PPE as standard. Steps ensure cleaning validation in processing zones, especially with cephalosporin cross-contamination risks.
Toxicity varies by route of administration, with parenteral animal studies informing process exposure controls. Downstream pharmaceutical clients require trace-level impurity tracking, especially for known immunogenic components. Staff undergo routine monitoring and medical assessment to preempt cumulative exposure effects.
Exposure controls use a risk-based approach, integrating air shower entry, exhaust hoods, and split charging to reduce powder airborne release. PPE selection considers grade being manufactured and scale. Production facilities integrate engineering and administrative controls to hit occupational exposure targets, with health surveillance extended in high-run settings.
Cefotaxime Sodium manufacturing hinges on production scale, reactor turnover frequency, and downstream purification capabilities. Available output aligns with the installed fermentation and synthesis train volume, which may be adjusted seasonally or by regulatory quota. Major output increases follow the commissioning of new facilities or process intensification. Product in stock for immediate shipment tends to reflect forecasted demand and customer call-offs on term contracts. Order fulfillment for large-volume APIs rarely draws on finished-goods inventory and instead triggers freshly scheduled campaigns to match batch consistency standards required by regulated regions.
Lead time depends on batch process scheduling and downstream QC release cycles. For established commercial grades destined for export, typical lead times reflect process, purification, and thorough quality record review. MOQ remains case-dependent, driven by batch size, packaging run economics, and client regulatory environment. Commercial buyers sourcing for injection use or regulated formulations typically must satisfy higher MOQs to align with full-batch traceability and validated cleaning cycles.
Packaging varies by route-to-market and target country registration. Bulk quantities favor multi-layer fiber drums with foil lining for protection against moisture and light. Smaller-scale, high-purity requests are packed in aluminum composite bags inside secondary rigid containers to mitigate cross-contamination and guarantee stability for pharma audits. Custom packaging for clinical or pilot projects can be performed under documented change control with pre-approval from the client.
Shipment practices depend on customer requirements and customs regulations. Temperature-controlled shipping is routinely applied for US, EU, and Japan orders due to stability data from ICH guidelines. Payment terms adjust to customer background: long-term partners often receive net payment terms, while new business relationships begin with partial advance or full prepayment. Incoterms offered depend on destination, regulatory burden, and available logistics partners.
The price of Cefotaxime Sodium correlates directly with costs for core intermediates—most notably, the 7-ACA nucleus and specialized acylating agents. Plant-based supply volatility for 7-ACA, energy price fluctuations, and environmental compliance costs in China and India frequently drive swings in base cost. Route optimization and alternative sourcing can reduce exposure, but long-term purchase agreements often lock in base loads to avoid acute spikes.
End-use grade remains the primary price differentiator. Injectable-grade material produced under cGMP fetches a significant premium compared to technical or vet applications. Analytical purity, residual solvent control, and microbial endotoxin levels structure the certificate-dependent price brackets. Packaging requirements tied to EU/US DMF registrations or Japan’s PMDA dossier demand extra batch-release analysis, adding further cost layers.
Higher purities and traceability demand intensified purification and testing, creating visible price separation between API for parenteral and non-parenteral formulations. Price tiers follow GMP documentation burden, validated cleaning and segregation needs, and post-sale pharmacovigilance obligations. Regulatory inspection history for the producing site also plays a role in negotiation outcomes and long-term contract pricing.
Production capacity is heavily concentrated in China and India, due largely to integration with upstream fermentation for penicillin and cephalosporin intermediates. EU and US production, while smaller in capacity, commands high regulatory and compliance premiums. Spot market tightness occasionally emerges from plant shutdowns for GMP upgrades or crackdown on wastewater discharge, triggering short-term price volatility.
In the US and EU, procurement depends on DMF status, QP declaration support, and finished formulation market pricing. Japan’s importers emphasize strict lot-specific documentation and cold chain integrity. India’s domestic capacity satisfies local needs, supported by robust raw material inputs. In China, oversupply and regulatory interventions periodically reshape export pipelines and swing price bands.
Forward-looking price forecasts draw on core raw input cost forecasts, regulatory outlooks, and market trade data from recognized pharma analytics agencies. Rising compliance costs in China’s antibiotic clusters and increasing API traceability requirements in Western markets signal sustained upward pricing pressure toward 2026. Upside risks: further raw material environmental regulation or major plant relocation. Downside risks: breakthrough catalysts, route change, or global demand contraction from rationalized antibiotic use.
Recent years have seen intensified scrutiny of manufacturing waste streams and periodic plant inspections in primary producing regions. Documented cases of batch supply diversion to higher-paying export markets have altered pipeline availability and downstream price realization.
API licensing and periodic re-inspections set an industry benchmark for batch-level document chains and DMF maintenance. Enforcement of stricter wastewater discharge in China’s major API zones has increased variable production costs—these ultimately flow downstream to contract pricing. Implementation of serialization and digital batch records continues to rise as a global theme, especially within the EU and US frameworks.
Manufacturers actively invest in greener process routes, internal consumption reduction, and expansion of digital QMS infrastructure. Diversification of raw intermediate sources and continuous validation campaigns help dampen sudden cost increases due to single-source supply choke points. Proactive regulatory engagement and regular GMP site upgrades remain essential to securing long-term contracts with multinational formulators.
Cefotaxime Sodium serves a broad segment of the pharmaceutical supply chain. Our production teams encounter the following major industry segments:
| Application Field | Matching Grade(s) | Critical Selection Factors |
|---|---|---|
| API for Parenteral Use | USP/EP/JP/CP | Regulatory compliance, particulate control, pyrogen/endotoxin levels, validated impurity profile |
| Bulk Synthesis (Intermediate) | Technical/Industrial | Main assay, impurity range, solvent residue, stability in logistical cycle |
| Analytical/Research | Reference/Test Standard | Traceability, purity certificate, batch documentation, sample size flexibility |
During manufacturing, we monitor several parameters that affect grade assignment and usability:
Confirm whether your use case involves direct pharmaceutical formulation, intermediate synthesis, or analytical research. API grades suit finished drug manufacturing, while technical and reference grades serve synthesis and testing workflows.
Check the monograph or regulatory standard relevant to your territory (USP, EP, JP, CP, or custom specification). Parenteral use mandates compliance with local and international pharmacopeial standards and audit trail requirements.
Specify minimum acceptable assay value and impurity profile for your downstream process. Lower threshold limits must match finished product target specification and may vary by marketing authorization or registration region.
Quantify batch or campaign size and forecast delivery windows. Higher volume orders sometimes unlock process economies at the cost of narrower batch-specific customization. Production planning aligns technical capability with batch frequency and resource allocation.
Initiate sample evaluation under actual process conditions. Realistic compatibility testing in your facility will highlight any regional, process-specific, or scale-driven variances beyond COA averages. Direct feedback links our batch control feedback loop with genuine end-use observations.
Consistent Cefotaxime Sodium quality begins with the structure of our management systems. Our site is independently audited for international standards on quality management, traceability, and risk analysis. Audit results and certification renewals are available for review by procurement teams with an NDA. Both process and product documentation align with current Good Manufacturing Practice (cGMP) protocols, and manufacturing oversight is led by quality assurance teams experienced in regulatory and customer audits.
Batch release is supported with full documentation from incoming raw materials through batch processing records and finished product test reports. Standard supply for regulated markets uses grades that comply with pharmacopeial monographs, including Ph. Eur., USP, or other regional requirements by agreement. Halal and Kosher certificates, as well as declarations of BSE/TSE status and residual solvent compliance per ICH Q3C, are available for qualifying batches. Dual documentation applies where product is used for formulary registration with multiple health agencies.
Technical dossiers include up-to-date Certificates of Analysis, process validation summaries, and impurity profiles for each lot. Change notification procedures follow agreed timelines. Stability protocols are defined by grade and market, with ongoing stability data available for procurement-controlled lots. Audit and inspection summary reports from external inspectors are available to authorized partners under mutual confidentiality terms.
We match annual production planning to forecasted demand by engaging with customer purchasing teams at the frame agreement stage. Fluctuations in demand are addressed by split manufacturing between main and auxiliary production lines, and by keeping strategic inventories of key intermediates and finished goods. For higher-volume or multi-year contracts, custom stocking and reserved campaign production plans reduce lead time variation and support smoother downstream scheduling.
Raw material procurement is locked in through multi-source supply agreements and close supply chain monitoring. We maintain alternate supplier validation for critical inputs as a standard risk mitigation step. Internal batch release criteria exceed statutory norms for lot-to-lot consistency, targeting minimized variability in key chemical properties as batch validation data demonstrate. Product grade is aligned to customer-specific process or formulation criteria, and we work with partners to incorporate process modifications when downstream requirements shift.
Sample requests follow a formal internal approval and logistics flow. Sample designation, batch selection, and release documentation are managed by the applications support team, with technical data shared under sample evaluation agreements. Instructions for sample storage and handling, including stability and requalification advice for laboratory- or pilot-scale use, are included with each dispatch. Feedback from evaluation batches supports process or grade revision requests.
We support both spot procurement and long-term collaboration frameworks. Long-term agreements can include price adjustment mechanisms, reserved capacity blocks, and custom labeling or packaging configurations. Clients with frequent regulatory filing cycles benefit from data sharing and advance notification of non-routine changes. For partners requiring rapid product qualification or custom process adaptation, technical exchange meetings are scheduled between our process engineers and customer R&D, with detailed minutes and follow-up action lists. Special requirements for delivery timing, quality documentation, or batch reservation are formalized in the supply contract and reviewed in joint steering meetings every quarter.
Current research on cefotaxime sodium focuses on strain improvement for fermentation efficiency, impurity profile optimization, and crystal morphology. Producer strains, substrate selection, and process route consistency remain under constant scrutiny as even slight deviations affect both yield and downstream purification. R&D accelerates on solvent-minimizing crystallization steps and on impurity mapping, especially for β-lactam-related and process-derived impurities. Analytical teams monitor trace-level byproducts as these drive both process redesign and final product stability strategies.
In clinical and hospital pharmacy settings, new interest centers on cefotaxime’s role in tackling multi-drug resistant pathogens. This drives projects targeting specialized dosage forms and advanced delivery systems, particularly for injectable formulations sensitive to pH and solvent residues. Some development groups now examine cefotaxime sodium as part of combination therapies, requiring even tighter control of particulate and microbiological quality. Veterinary and livestock sectors periodically request tailored material grades to comply with regional residue limits or solubility profiles, impacting both process train and validation logic on our side.
High-throughput monitoring for side products and the persistence of late-eluting polar impurities pose ongoing technical hurdles. Persisting β-lactam degradation during sterilization steps remains a bottleneck for shelf-stable formulations. Several process engineering projects have improved batch homogeneity by refining crystallization temperature and agitation profiles, yet scale-up occasionally exposes hidden endpoint variability. Continuous feedback from applied analytics, including LC-MS impurity profiling and real-time in-process HPLC, now allows faster refinement of both upstream and downstream control points.
Clinical demand for cefotaxime sodium remains steady across public health and emergency stockpiling sectors, with regional fluctuations in procurement cycles. Latin America, parts of Eastern Europe, and selected Asian markets project increased requirements due to shifts in hospital formulary preferences and antimicrobial stewardship policies. Formulation manufacturers increasingly require both standard and premium grades differentiated by pyrogen and particulate levels.
Process intensification and digitalization, integrating advanced PAT (Process Analytical Technology), are becoming routine on commercial lines. Process innovations focus on solvent reduction and improved recycle ratios to lower effluent loads. Protein and endotoxin removal have shifted toward microfiltration and membrane systems, driving down total bioburden.
Green chemistry principles influence the supply chain all the way from β-lactam precursor sourcing to solvent and water use minimization. Manufacturing lines now pilot eco-friendlier crystallization agents for mother liquor recovery, lowering environmental impact. Continuous improvement projects address effluent treatment, energy consumption, and waste minimization as routine audited criteria during internal and third-party inspections. Procurement increasingly selects raw material streams with reduced carbon footprint, provided they meet strict process compatibility criteria.
Manufacturing technical teams handle inquiries on both standard and application-specific grades, supplying guidance on selection based on impurity demands, particle size distribution, or solubility in direct-use systems. Typical discussion topics include reconstitution protocols, interaction with specific diluents, and compatibility within defined storage conditions. Custom documentation, including extended impurity profiling, can be supplied according to regulated market submissions or specialized applications.
Product specialists assist formulation groups in selecting appropriate cefotaxime sodium batches to stabilize pH and minimize physical degradation in lyophilized injectables. When customers face issues such as precipitation during compounding, technical service investigates batch history, crystallization profile, and packing configuration. Support extends to both routine and regulatory-driven change management, adapting raw material control logic as needed to synchronize with customer validation runs.
Each release batch includes a full set of quality control documents, including process route declaration and a supply chain trace file if required for regulated use. Batch recall procedures comply with internal traceability and customer-specific notification agreements. Once delivered, our technical liaison monitors shipped lot performance through periodic customer feedback, enabling rapid response to quality concerns or post-market surveillance findings. Ongoing support adapts to new regulatory requests or modifications in customer process trains, sustaining both compliance and operational continuity.
Producing Cefotaxime Sodium requires vertical discipline over fermentation, extraction, and crystallization. At our plant, we oversee each stage from culture selection through final drying. Long-term staff and established protocols guide every batch. This end-to-end control keeps specifications tight and supply chains lean, with fewer variables than fragmented manufacturing models. Our output supports pharmaceutical intermediates, veterinary preparations, and contract pharmaceutical formulators who need steady quality and traceability.
Bulk Cefotaxime Sodium forms the foundation for commercial antibiotic manufacturing. API producers, veterinary medicine firms, and hospital compounding operations utilize our product in injectable solutions, powder blends, and direct tableting. Long runs, consistent yields, and regulatory-compliant methods make the material suitable for commercial downstream processing. Our material delivers predictable compatibility and low byproduct levels for integrators scaling up.
Analytical results matter. Each batch moves through in-process chromatographic monitoring and plate viability checks. Final quality control includes identity, potency, and impurity profiling. Production records match outgoing lots to unique retention samples, creating full batch histories. Regulatory audits and customer technical teams can review trace documents, as all data and samples stay on-site. We do not rely on third-party labs for test verification.
We fill vials and drums in filtered, climate-controlled zones connected directly to production lines. Cold-chain or controlled ambient shipping protocols match market requirements, and large format packaging reduces handling steps at the customer site. Wide output capacity enables us to meet high-volume orders and specialty line runs. Export certifications follow every load, optimized for processing at customs and industrial unloading points.
Process chemists and plant engineers often need rapid answers during tech transfer or scale-up. Our technical staff has both bench and plant-scale experience, allowing flexible problem-solving for buyers. We assist in solubility, filtration, and reconstitution projects while referencing real lab data instead of theoretical projections. Troubleshooting focuses on batch performance and formulation compatibility.
Direct partnerships with our factory eliminate intermediary handling, offering transparent production schedules and shipment tracking. Buyers receive fixed terms, batch release forecasts, and safety stock options. Our on-site inventory system adjusts to rapid changes in demand, supporting short lead times for critical manufacturing programs. By controlling every link from raw input to export packaging, we drive out hidden costs and production delays.
Sustained investment in new lines and process controls keeps us ahead of variable regulatory and market demands. Our product supports pharmaceutical, veterinary, and industrial medicine markets requiring rigorous, reproducible antibiotic intermediates produced under real factory control.
Every year, our facility handles thousands of batches of cefotaxime sodium, both as bulk powder and in finished forms. There’s always one pressing question from partners, pharmacists, and healthcare providers: how stable is cefotaxime sodium after reconstitution, and where should it be kept? Daily, our technical and quality teams monitor, sample, and test stability under different storage conditions in order to prevent the loss of potency and to avoid risk of degradation products. This is not just regulatory compliance — it's about safeguarding the end effectiveness for clinicians and their patients.
Our own validation studies align with the published literature and pharmacopeial guidelines. Once reconstituted, cefotaxime sodium solutions show the greatest stability at 2–8°C, which means refrigeration. At this temperature range, our records show that a freshly reconstituted solution can maintain its chemical integrity and visual clarity for up to 24 hours. We avoid the use of old solutions because breakdown products do form after that, even if color change is not obvious. This aligns with the risk management protocols in our production and packaging lines — all finished goods move through temperature-controlled environments before dispatch.
At room temperature (20–25°C), the compound degrades more quickly. Testing runs completed by our analytical team demonstrate that a reconstituted solution kept at room temperature will begin significant degradation after just six hours. We always flag this in our official guidance: if storage in a refrigerator is not available, the solution should be used as quickly as possible, and never later than six hours after mixing.
The chemical structure of cefotaxime sodium includes a beta-lactam ring, which is sensitive to hydrolysis. Water triggers ring opening and loss of antibiotic properties — our stability data reflects this sensitivity. That is why we recommend preparing the solution immediately before use, limiting the time in solution even if refrigeration is available. In our process development, even the choice of diluent comes under review: some hospital units use sterile water, others use saline or dextrose. Our tests repeat across these variations, and results consistently show similar timelines for acceptable quality.
A common misconception arises from the visual appearance of the solution. Sometimes partners tell us that the solution stays clear for longer periods, thinking it remains usable. From our side, we emphasize that visual clarity does not guarantee chemical stability. Lab analysis is the only way to confirm actual antibiotic concentration, and degradation can occur well before any cloudiness appears.
Our quality team ensures that every lot comes with detailed storage and handling guidance. We recommend that all unused reconstituted product gets discarded after the recommended period. From the manufacturing site, logistic control keeps all stocks in dry, controlled warehouses at less than 25°C and protected from light, but once vials are mixed with diluent, timing becomes critical. We reinforce this point constantly in our technical training and printed documentation.
Ultimately, stability hinges on prompt use and proper temperatures. To guarantee optimal results with our cefotaxime sodium, our partners and customers benefit from years of controlled real-world data and strict laboratory oversight. Any new questions or needs for alternate packaging solutions, our technical team is ready to share findings and recommendations proven across many production cycles.
Every stage of producing Cefotaxime Sodium starts with clear, transparent communication about expectations. We do not take commitments lightly, especially when medicine supply impacts patient care and downstream partners. Over several decades, we have learned that reliability begins with straightforward discussions of order conditions—most notably, minimum quantities and production timing.
Unlike smaller trading operations, our manufacturing footprint is designed for batch production to ensure consistent product quality. Batch size, not arbitrary contract size, forms the basis for our minimum order quantity. The synthesis, crystallization, drying, and packing lines are configured to minimize variation between runs. Typical industrial lots for Cefotaxime Sodium start around 20 to 50 kilograms. Orders smaller than that introduce operational inefficiencies, both for quality assurance and production handling. Each batch undergoes full testing—identity, purity, microbial limits—and a full documentation cycle. These efforts demand resources that make sense at certain thresholds. By setting the minimum at a practical level, our clients receive material from fresh lots, supported by the batch history required from regulatory authorities. For special projects, we evaluate capacity and logistics jointly—but we base our discussions on real facility constraints, never on guesswork.
Shipping timelines require as much transparency as order size. For routine lots kept in inventory, delivery often takes less than two weeks, including documentation and export clearance. For custom specifications or situations where forecasts indicate above-average demand, production aligns with our scheduling window. That usually means a four-to-six-week lead time from receipt of the confirmed purchase order. API production includes raw material procurement, validation of current impurity profiles, finished product assays, and repeat checks on antimicrobial activity. The most common delays relate to documentation—regulatory filings, Certificate of Analysis approval, or changes in national requirements around antibiotics.
Repeated experience with global supply chain interruptions has refined our ability to respond quickly. By investing in local API and key intermediate suppliers, we have shortened lead times and reduced exposure to cross-border disruptions. Our logistics division routinely monitors freight corridors and regulatory developments, so we adjust shipment methods before bottlenecks hit. Urgent orders due to hospital shortages or clinical trial needs receive immediate attention—we organize dedicated production slots or partial lot releases whenever technical and compliance risk allows.
Our technical support team closely tracks each production campaign with the ordering partner, so information flows both ways. Shipping schedules, documentation arrivals, and updates about any raw material supply changes are shared in real time. We provide detailed batch dossiers on request. For partners scaling up, we share stability data packages, impurity trend reports, and manufacturing insights learned from past campaigns. Addressing both regular and unique orders relies on consistent manufacturing practice, clear specification control, and collaboration at every stage.
We have seen that honest minimum order quantity policies and realistic lead times support our customers’ ability to plan inventory, respond to market pulls, and keep patients supplied. Our process improvement teams work to refine cycle times and strengthen communication between planning, QA, and sales. The information provided on order sizes and delivery slots is grounded in daily production experience. Through collaboration, technical transparency, and operational discipline, the supply of Cefotaxime Sodium remains dependable and safe.
In antibiotic manufacturing, strict compliance with current Good Manufacturing Practice (cGMP) standards forms the backbone of our entire operation. As a direct producer of Cefotaxime Sodium, we continuously update our manufacturing processes in alignment with evolving international health regulations. The system runs on rigorous oversight, routine process validation, and robust staff training. Every stage, from sourcing of raw materials to final packaging, undergoes documented review and controls to eliminate deviations that can influence quality.
Our facility runs on validated equipment following established cleanroom procedures, environmental monitoring, supplier audits, and comprehensive in-process checks. Each lot of Cefotaxime Sodium passes through multi-tier in-house testing, including identity, potency, impurities, sterility, and pyrogenicity. Process records are meticulously maintained. Audits, both internal and by regulatory bodies, are routine, not exceptions.
Stringent pharmaceutical export regulations can frustrate some exporters, but for a manufacturer, these requirements foster reliability. We do not view regulatory demands as mere paperwork. For every shipment, export files include the Certificate of Analysis, Batch Manufacturing Records, GMP Certificates, and detailed third-party analytical results if requested. We maintain well-organized archives for all documentation, which remains accessible for regulatory inspection or customer requests.
Some regions require additional authorizations: for example, a Certificate of Pharmaceutical Product (COPP), or legalized documents for specific destination markets. Our regulatory group prepares and tracks these, allowing the customs clearance process to proceed without delay. Such documentation confirms that each batch stems from GMP-approved lines, tracked through unique batch numbers linked to full production histories.
Maintaining batch-to-batch reproducibility represents a daily challenge, particularly with cephalosporin antibiotics. Variability in raw material supply or utilities can impact consistency. We run audit trails for every process deviation and corrective action. This effort translates into reliable product quality, lower recall risk, and confidence for pharmaceutical partners. If a country’s regulations shift, our in-house team pivots manufacturing or release strategies without interrupting supply.
Counterfeit documentation and improper warehousing pose real threats in the global pharma chain. We offer advanced product traceability tools, including tamper-evident packaging and QR code tracking, enabling downstream partners and customs to verify each delivery directly against our database. This direct verification cuts the risk of leakage into grey channels, upholds our brand, and protects our end user.
Our commitment to GMP compliance extends beyond internal quality controls. Investment in new technologies and continuous staff training remains a priority. Digital batch records, advanced chromatographic analysis, and improved containment systems ensure we meet—and anticipate—future compliance requirements. The result: Cefotaxime Sodium that meets international pharmacopeias, backed by export files ready for swift global movement.
As the original manufacturer, our technical specialists directly support customers seeking regulatory or quality documentation. We do not outsource responsibility. From plant floor to export dock, our process combines accountability, transparency, and technical precision.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
